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ABSTRACT
The use of short interfering RNAs (siRNA) in animals
for target validation or as potential therapeutics is
hindered by the short physical half-life when de-
livered as unencapsulated material and in turn the
short active half-life of siRNAs in vivo. Here we dem-
onstrate that the character of the two 30-overhang
nucleotides of the guide strand of siRNAs is a de-
terminant of the duration of silencing by siRNAs
both in vivo and in tissue culture cells. We demon-
strate that deoxyribonucleotides in the guide strand
overhang of siRNAs have a negative impact on
maintenance of both the in vitro and in vivo activity
of siRNAs over time. Overhangs that contain
ribonucleotides or 20-O-methyl modified nucleotides
do not demonstrate this same impairment. We also
demonstrate that the sequence of an siRNA is a
determinant of the duration of silencing of siRNAs
directed against the same target even when those
siRNAs have equivalent activities in vitro. Our
experiments have determined that a measurable
duration parameter exists, distinct from both
maximum silencing ability and the potency of
siRNAs. Our findings provide information on
incorporating chemically modified nucleotides into
siRNAs for potent, durable therapeutics and also
inform on methods used to select siRNAs for thera-
peutic and research purposes.
INTRODUCTION
Over the past quarter century, several generations of
potential therapeutic nucleic acid technologies have been
brought forward for clinical development. These include
antisense oligonucleotides, ribozymes, aptamers and now
siRNAs. The ubiquitous presence of nucleases in biologic-
al settings and consequent physical instability of RNA and
DNA outside cells has led most nucleic acid drug
developers to pursue chemical modiﬁcation of the active
nucleic acid entity. These modiﬁcations—either to the
phosphodiester backbone, the base, or the sugar—can
result in dramatic improvement in physical stability in
animal or human serum (1,2). However, naked siRNAs,
even when extensively chemically modiﬁed and highly
active in vitro, have been shown to have unacceptable
pharmacokinetic properties in vivo, being rapidly cleared
through the kidney in rodents (3). These properties
severely limit the use of siRNA for systemic applications
without a more sophisticated mode of delivery. A variety of
delivery technologies that minimize renal clearance have
been explored, including conjugation of ligands to the
siRNA to facilitate cellular uptake (4), polymeric cages to
encapsulate siRNA and lipid-based nanoparticles, which
are designed to be taken up into endosomes and subse-
quently escape, releasing their cargo into the cytoplasm
where the siRNA responsive machinery is located.
Recent approaches with siRNA given systemically have
utilized sugar-modiﬁed siRNAs encapsulated in lipid-
based nanoparticles to eﬃciently deliver siRNA to thera-
peutic targets of interest in the liver (5,6). An important
question raised by these studies was the interplay between
chemical modiﬁcation of the siRNA and the type of
delivery vehicle in determining eﬃciency of target
knockdown in vivo. For example, if a siRNA is eﬃciently
encapsulated and protected from serum nucleases, does
chemical modiﬁcation have an impact on duration of
silencing in vivo? Also, siRNAs have been shown to
trigger unwanted inﬂammatory responses in vitro and
in vivo via interaction with toll-like receptors (TLRs) or
other pattern recognition receptors (7). These receptors
are located on plasma or endosomal membranes as well
as in the cytoplasm where they monitor the presence of
pathogen-derived macromolecules. Do chemical modiﬁca-
tions that abrogate activation of these receptors (5,8) also
have an impact on duration of silencing in vivo?
Previous reports have indicated both positive and
negative eﬀects of patterns of chemical modiﬁcation on
speciﬁc properties of siRNAs such as resistance to serum
nucleases, reduction of target mRNA target levels and
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below focused speciﬁcally on the two 30-overhang nucleo-
tides of the guide strand of the siRNA to examine the
eﬀect of chemically modiﬁed nucleotides on the silencing
and duration of silencing both in vitro and in vivo.
Within the ﬁeld, the original motivations for using
deoxythymidine nucleotides as the overhang nucleotides
in siRNAs were related to cost, availability and ease of
synthesis of the siRNAs when utilizing these nucleotides,
as well as increased stability of the oligos to serum nucle-
ases (9). In addition, the authors reported no detectable
loss of activity of the siRNAs that was dependent upon
the character of the nucleotides as long as the length of the
overhang was two nucleotides. However, other reports
have demonstrated that the character of the 30-overhang
of the guide strand is a determinant of strand selection
(10), and that the 30-overhang on the guide strand inter-
acts with the PAZ domain of RISC in the RNA-binding
pocket (11), suggesting that the overhang does in fact have
a possible contribution to siRNA activity. In contradic-
tion to the original observation that deoxythymidine nu-
cleotides in the guide strand overhangs have little negative
consequence on silencing, other reports have made the
observation that these overhangs can reduce maximal
silencing activity of siRNAs (12,13).
We demonstrate that the nucleotide content of the guide
strand overhang appears to have little or no eﬀect on
maximum silencing in vitro. However, we also show that
minor diﬀerences in the character of the overhang nucleo-
tides of a siRNA guide strand have a profound eﬀect on
the duration of silencing. Finally, we demonstrate that
siRNAs that have very similar capacities for reduction
of mRNA levels in tissue culture cells and in vivo have
distinct durations of silencing that are appear dependent
upon the composition of the siRNA.
MATERIALS AND METHODS
Design of siRNAs
The siRNA sequences used in this article were designed
using a previously described algorithm (14) developed to
predict silencing eﬃcacy in unmodiﬁed form with two
deoxythymidine nucleotides as the overhang.
The four siRNA sequences used for the in vivo studies
have the following sequences (all in the 50–30 direction)—
where XX indicates the various guide strand overhangs
described in this work; Seq1 Passenger CUCUCACAUA
CAAUUGAAATT, Seq1 Guide UUUCAAUUGUAUG
UGAGAGUUXX; Seq25 Passenger CUCCUAUAAUG
AAGCAAAATT, Seq25 UUUUGCUUCAUUAUAGG
AGUUXX; Seq37 Passenger CUUUAACAAUUCCUG
AAAUTT, Seq37 Guide AUUUCAGGAAUUGUUAA
AGUUXX; Seq40 Passenger UCAUCACACUGAAUA
CCAATT; Seq40 Guide UUGGUAUUCAGUGUGAU
GAUUXX. All other siRNA sequences are in
Supplementary Table S1.
Cells and reagents
The mouse hepatoma Hepa 1-6 cell line was obtained from
the American Type Tissue Collection (Cat # CRL-1830).
Cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(Mediatech, Cat #10-013-CV) with 4mM L-glutamine
adjusted to contain 1.5g/l sodium bicarbonate and 4.5g/l
glucose and supplemented with 10% of fetal bovine
serum, 100mg/ml of streptomycin and 100U/ml penicillin.
Cells were cultured at 37 C in the presence of 5% CO2.
Preparation of synthetic siRNAs (in vitro experiments)
SiRNAs for the in vitro experiments were ordered from
Sigma-Aldrich. A total of 40 sequences were ordered, each
being synthesized with four diﬀerent guide strand over-
hangs; ribonucleotides complementary to positions  1
and  2 in the target mRNA (rN-rN), 20-O-methylated
complementary nucleotides (oN-oN), deoxythymidine
overhangs (dT-dT) and 20-O-methyl-uridine overhangs
(oU-oU).
Preparation of synthetic siRNAs (in vivo experiments)
The siRNAs used in the in vivo studies were synthesized by
methods previously described (15). For each oligonucleo-
tide, the two individual, complementary strands of the
siRNA were synthesized separately using solid phase syn-
thesis, then puriﬁed separately by ion exchange chroma-
tography. The complementary strands were annealed to
form the double strand siRNA (duplex). The duplex was
then ultraﬁltered and lyophilized to form the solid drug
substance. The duplex material was tested for the presence
of endotoxin by standard methods.
Preparation of siRNA–lipid nanoparticle complex
Lipid nanoparticles (LNPs) were made using the cationic
lipid CLinDMA (2-{4-[(3b)-cholest-5-en-3-yloxy]-butoxy}-
N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-
propan-1-amine), cholesterol, and PEG-DMG
(monomethoxy(polyethyleneglycol)-1,2-dimyristoylglycerol)
in 50.3:44.3:5.4 molar ratio. siRNAs were incorporated
in the LNPs with high encapsulation eﬃciency by mixing
siRNA in buﬀer into an ethanolic solution of the lipid
mixture, followed by a stepwise diaﬁltration process.
Cholesterol was purchased from Northern Lipids,
PEG-DMG was purchased from NOF Corporation and
CLinDMA was synthesized by Merck and Co. The encap-
sulation eﬃciency was determined using a SYBR Gold
ﬂuorescence assay and the particle size measurements
were performed using a Wyatt DynaPro plate reader.
The siRNA and lipid concentrations in the LNP were
quantiﬁed by a HPLC method, developed in house,
using a PDA detector.
Transfection of siRNAs for screening
Cells were plated in 96-well plates at 5000 cells/well and
transfected at a ﬁnal siRNA concentration of 10nM using
RNAiMax (Invitrogen, Cat #13778150) according to the
manufacturers speciﬁcations. Cells were lysed 24h after
transfection.
RNA was isolated by preparing lystates from the cells
on a Biomek FX liquid handler using Cells-to-Ct Bulk
Lysis and Stop Reagents (ABI, Cat #4391851C) according
to the manufacturer’s instructions.
Nucleic Acids Research, 2010,Vol.38, No. 14 4789In vitro duration assay (RNAiMax transfection)
A plate for transfection of the cells was prepared such that
each siRNA was represented in six diﬀerent random loca-
tions on the plate. This was done to address concerns
about well-to-well variability in transfection and/or
growth of cells over the long time course of the
experiment.
Cells were plated in 96-well plates at 1200 cells/well and
transfected at a ﬁnal siRNA concentration of 10nM using
RNAiMax (Invitrogen, Cat #13778150) according to the
manufacturers speciﬁcations. Cells were lysed 24, 48, 72,
96 and 120h after transfection.
Transfection of LNP formulated siRNAs into tissue
culture cells
Transfections of LNPs were performed in six replicates in
two replicate experiments (three replicates/experiment).
Cells were plated in 96-well plates at 3500 cells/well. The
ﬁnal concentration of siRNA in each well was 120nM.
The time of incubation with the LNP-siRNA complexes
was 24 and 120h. Media change was performed every 48h
from the time cells were plated by replacing 75ml with
fresh complete growth culture media until the 120h time
point.
RNA was isolated by preparing lystates from the cells
on a Biomek FX liquid handler using Cells-to-Ct Bulk
Lysis and Stop Reagents (ABI, Cat #4391851C) according
to the manufacturer’s instructions.
RNA isolation from in vivo study samples
C57BL/6 mice were dosed with 3mg/kg siRNA (in LNP)
and sacriﬁced at various time points. Cohorts for controls
and each siRNA tested consisted of ﬁve animals.
Blood and liver samples were collected immediately fol-
lowing euthanasia.
Total RNA was isolated from liver tissue using the
RNeasy 96 Tissue Kit for high-throughput 96-well RNA
minipreps (Qiagen, Cat #74881) and a QIAvac 96 vacuum
manifold according to the manufacturer’s instructions. All
RNA samples were treated with DNase I (Qiagen, Cat
#79254) on column for 15min at room temperature.
Final RNA eluted was quantiﬁed and normalized to a
concentration of 50ng/ml.
Reverse transcription and PCR
cDNA was generated from lysates and RNA in a 20ml
reaction using reverse transcription reagents from the
Ambion Cells-to-Ct Kit (Applied Biosystems, Cat
#4368813) according to the manufacturer’s instructions.
On an ABI 7900 HT real-time PCR System, quantitative
real-time PCR was carried out in a 384-well plate.
Reactions were set up in duplicate and one well was
probed with the Apob Taqman reagents, the other with
the GAPDH Taqman reagent in a ﬁnal volume of 10ml
using TaqMan Gene Expression Master Mix (Applied
Biosystems, Cat #4370074). All Taqman probes and
primers were supplied as prevalidated sets by Applied
Biosystems: mouse GAPDH, Cat #4352339E; mouse
Apob, Assay ID Mm01545154_g1.
Taqman data analysis
The Taqman data were analyzed by standard methods on
an ABI 7900 instrument. Within each experiment, the
baseline was set in the exponential phase of the ampliﬁca-
tion curve, and based on the intersection point of the base-
lines with the ampliﬁcation curve; a Ct value is assigned by
the instrument. The expression level of the gene of interest
and percentage knockdown was calculated using com-
parative Ct method:
Ct ¼ CtTarget   CtGAPDH
Ct ¼ CtðTarget siRNAÞ CtðNTCÞ
Relative expression level ¼ 2 Ct
%K D¼ 100  ð 1   2
 CtÞ
The mRNA knockdown was calculated relative to a
non-targeting control siRNA in each experiment.
Cytokine quantitation
Cytokine levels were measured in mouse serum using the
SearchLight Mouse IR Cytokine Array, 12-plex assay
(Thermo Fisher Scientiﬁc, Waltham, MA) according
to the manufacturer’s instructions. Data were acquired
with the Odyssey Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE) and analyzed with
SearchLight Array Analyst Software.
Statistical analysis
Unless otherwise noted, datasets were compared using a
two-tailed Student’s t-test to generate P-values. Also,
unless otherwise noted, statistical analyses were performed
using the data expressed as log2-fold change rather than in
percent expression or percent knockdown of the mRNA
transcript, as the logarithm of Taqman error is uniformly
distributed, and the logarithm of target-normalized
siRNA silencing is normally distributed.
Calculation of retention rate of silencing
To calculate the retention rate of silencing both in vitro
and in vivo, we converted the percent knock-down values
at the relevant timepoints to  log2-fold change (ddCt
values from Taqman), subtracted the early timepoint
value from the later timepoint value and divided by the
number of days between the two timepoints. This gave us
a value for the fraction of silencing seen at the ﬁrst
timepoint that was lost per day up to the second
timepoint.
RESULTS
In vitro eﬃcacy of chemically modiﬁed siRNAs
In this study, we examined the eﬀects of varying the over-
hanging nucleotides of the guide strand of a standard
21 nucleotide duplex siRNA in several assays. We chose
to examine four diﬀerent guide strand overhangs. We
selected deoxythymidime overhangs because they are the
de facto industry standard (9), ribonucleotides which
are complementary to positions  1 and  2 relative to
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overhang if the siRNA being examined were to be
produced naturally within a cell, and 20-O-methyl
modiﬁed nucleotides, either uridines to correspond to
the thymidines, or complementary nucleotides.
First, we examined the eﬀect of diﬀerent guide strand
overhang modiﬁcations on the extent of knockdown of the
target mRNA in tissue culture cells 24h post-transfection.
We compared overhangs of ribonucleotides complemen-
tary to positions  1 and  2 in the target mRNA (rN-rN),
20-O-methyl modiﬁed versions of those complementary
nucleotides (oN-oN), dexoxythymidine overhangs
(dT-dT) and to 20-O-methyl-uridine (oU-oU) overhangs.
In all cases, regardless of the guide strand overhang, the
passenger strand overhang was maintained as dT-dT to
experimentally isolate the eﬀect of the guide strand
overhang. Forty siRNA sequences directed against the
murine Apob gene were synthesized with these four
guide strand overhangs and tested in Hepa1-6 cells, a
mouse hepatoma-derived cell line, for their ability to
reduce the level of Apob mRNA.
The average degree of knockdown seen with the dT-dT
overhangs was 97.7±1.8%; with oU-oU, 97.0±4.4%;
with oN-oN, 98.3±.4; and with rN-rN, 97.2±2.3%.
These data can be found in Supplementary Table S1.
This similarity in knockdown between dT-dT overhangs
and rN-rN overhangs is consistent with previously pub-
lished reports on the activity of siRNA duplexes with
deoxyribonucleotides in guide strand overhangs (9)
though in disagreement with other published articles
which showed a detrimental eﬀect of dT-dT overhangs
compared speciﬁcally to rN-rN guide strand overhangs
(12) or to rU-rU overhangs (13). To compare the data
statistically, we converted the knockdown results to log2-
fold change to obtain a normal distribution of variance
across silencing levels allowing us to perform standard
parametric statistics. The data showed no systematic dif-
ference in the ability of siRNAs with these four diﬀerent
guide strand overhangs to reduce the target mRNA level
in tissue culture cells at 24h post-transfection (Student’s t-
test: oU-oU versus dT-dT, P=0.20; rN-rN versus dT-dT,
P=0.18; oN-oN versus dT-dT, P=0.12).
In vitro duration assays
In order to assess any diﬀerential eﬀect the sequences and
the guide strand overhangs had on the rate of recovery of
the expression of the Apob mRNA levels in vitro, we per-
formed assessments of the levels of mRNA reduction after
treatment with each of the 40 siRNA sequences in four
chemistries, for a total of 160 siRNAs each day from 1 to
5 days post-transfection. These data are summarized in
Supplementary Table S1.
We observed that even though all 40 sequences showed
extremely similar maximum mRNA reductions, the rate at
which the silencing activity was lost in vitro appeared to
have an siRNA-speciﬁc component as well as an
overhang-speciﬁc component. However, we were unable
to identify sequence motifs associated with increased or
decreased duration of silencing in this data set, perhaps
due to the limited number of sequences.
The data from these duration assays are summarized in
Figure 1. siRNAs with dT-dT overhangs consistently per-
formed more poorly over time than siRNAs with any of
the other tested overhangs. We quantiﬁed this by
comparing the knockdown results in log2-fold change
space at each of the individual timepoints (Figure 1).
Even by 2 days post-transfection the mean silencing of
siRNAs with dT-dT overhangs is signiﬁcantly reduced
relative to silencing of the same sequences to the oN-oN
overhang (P=0.013). The diﬀerence is increased by day 3
and now shows signiﬁcance to all three overahangs
(to rN-rN P<0.001; to oU-oU P=0.003; to oN-oN
P<0.001) this signiﬁcant diﬀerence is retained at day 4
(to rN-rN P<0.001; to oU-oU P<0.001; to oN-oN
P<0.001) and is slightly reduced by day 5 (to rN-rN
P=0.001; to oU-oU P=0.017; to oN-oN P=0.01),
probably attributable to an increasing number of se-
quences having no activity regardless of the guide strand
overhang at the latest timepoint.
In vitro dose response curves
To further evaluate the eﬃcacies of siRNAs with diﬀerent
guide strand overhangs, we selected four siRNA sequences
(Seq1, Seq25, Seq37 and Seq40) each with dT-dT, rN-rN,
oN-oN and oU-oU overhangs. Based on our in vitro ex-
periments, we expected rN-rN, oN-oN and oU-oU over-
hangs to behave equivalently. These four sequences were
selected on the basis of having comparable degrees of
mRNA reduction in our initial screens regardless of the
guide strand overhang tested (see Table 1). We also
determined in our subsequent experiments that the
sequences demonstrated a range of in vitro durations.
Seq40 appeared to have the most stable duration in our
in vitro assays, both Seq25 and Seq37 appeared to be
among the least durable siRNAs, and Seq1 fell between
those two extremes. We were interested in diﬀerences in
Figure 1. siRNA with diﬀerent guide strand overhangs were tested
over a time course in mouse Hepa1–6 cells. Each data point represents
results from: dT-dT n=39, oU-oU n=39, rN-rN n=40 and oN-oN
n=40 unique sequences. Asterisk indicates that the dT-dT data point
at that particular timepoint has a P-value of <0.05 compared with the
data points for each of the other three overhangs tested. Data are
expressed as mean±SEM.
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degree of reduction of the target and the relationship
if any of concentration dependence of silencing to
siRNA sequence or guide strand overhang. As shown in
Figure 2, siRNAs with the same target sequence but dif-
ferent guide strand overhangs shared similar IC50 values.
We did observe diﬀerences in the IC50 values between se-
quences. Notably Seq25 had an IC50 in all chemistries that
was  20-fold higher than that seen with the Seq40, and
 4 times higher than that seen with Seq37 (Figure 2).
In vitro duration assay with LNP formulated siRNAs
The four sequences in three chemistries described above
were formulated in a LNP-delivery vehicle. The
LNP-formulated siRNAs were transfected into cells, and
the cells were harvested 24and 120h post-transfection
(Figure 3). The 12 tested siRNAs showed an average of
96.2±1.3% reduction of the target mRNA at 24h, but by
120ha large range in the degree of knockdown was
observed.
Comparing the amount of activity lost between the 24-h
and 120-h timepoints in siRNAs with dT-dT overhangs,
one of the sequences lost 8.9% (from 94.5% mRNA re-
duction at 24h to 85.6% mRNA reduction at 120h) of
activity (Seq40), while another (Seq37) showed a loss of
76.2% of activity (from 95.6% mRNA reduction at 24h to
19.4% mRNA reduction at 120h) over the same time
period. The remaining two sequences (Seq1 and Seq25)
showed a loss of activity of 46 and 54%, respectively.
Comparing the sequences with oU-oU overhangs, we
observed losses of 16 (Seq1), 18.9 (Seq25), 25.1%
(Seq37) and no detectable loss in Seq40. When the over-
hangs were rN-rN, we observed losses of 8 (Seq1), 19.1
(Seq25), 11.2% (Seq37) and again no measurable loss in
Seq40. These data indicate that siRNA sequence and
overhang chemistry both likely play a role in determining
silencing duration.
An overall comparison of the loss of silencing activity
dependent on chemistry showed that the oU-oU and
rN-rN overhangs showed comparable losses of
14.9±10.9 and 9.9±7.6%, respectively between 24 and
120h, while the siRNAs containing dT-dT overhangs
showed a loss of 46.5±28.0%. The dT-dT loss of
activity had a P-value of 0.03 compared to oU-oU and
0.05 to rN-rN. The loss of activity with oU-oU overhangs
compared to the loss of activity with rN-rN overhangs had
a P-value of 0.23. In all cases dT-dT overhangs were dem-
onstrably worse in their ability to maintain silencing over
the time range tested in this assay.
In vivo eﬃcacy and duration
We had veriﬁed in vitro that the LNP-encapsulated
siRNAs retained the ability to comparably reduce Apob
mRNA levels 24h post-transfection (Figure 3).
Furthermore, the IC50s were virtually identical across
three guide strand overhangs, although showing some
sequence dependence (Figure 2).
To test duration of silencing in vivo and investigate the
contribution of siRNA sequence and guide strand
overhang modiﬁcation to in vivo duration, a single dose
of formulated siRNAs were delivered via the tail vein and
the degree of knockdown of Apob mRNA in liver was
examined at 1, 3, 7 and 14 days (Figure 4). In most
cases, siRNAs with all three of the guide strand overhangs
showed comparable degrees of knockdown at the shortest
timepoint measured (1-day post-treatment). The exception
was Seq37, which showed reduced day 1 knockdown
in vivo with the dT-dT overhang. This sequence had also
shown the largest degree of loss in the vitro duration assays
when the dT-dT overhang (Figure 3) was compared to
oU-oU or to rN-rN. As expected, in all cases there was
a loss of activity of the siRNAs over time. Diﬀerences in
the rate of loss of activity were in part due to siRNA
sequence. An example of this sequence dependent range
is shown in Figure 5, where the dT-dT versions of all four
sequences are compared, and the diﬀerence between the
durations of the sequences is clear. This diﬀerence is also
seen when comparing the four sequences in the other two
tested chemistries, though as we appear to approach the
maximum possible duration of action of the siRNAs
in vivo, the diﬀerences become less obvious.
We looked at several parameters of the siRNA activity
in vivo as a means to discern the diﬀerences between the
various guide strand overhangs (Table 1). We examined
the maximum degree of mRNA reduction and retention
rate of silencing activity per day. The values for these par-
ameters appear to be worse for dT-dT overhangs
compared to the other two overhangs for each of the






mRNA reduction in vivo
Retention rate
(in vivo) Days 1 to 7 (%)
Retention rate
(in vitro) Days 1 to 5 (%)
Time to 50%
knock-down (days)
Seq1 dT-dT 96.4±2.3 81.4±17.4 85.2 79.3 5
Seq1 oU-oU 97.6±1.8 92.0±7.1 88.8 85.9 10
Seq1 rN-rN 99.1±0.3 89.2±14.4 91.9 88.7 10.5
Seq25 dT-dT 99.4±0.4 78.0±3.8 91.8 78.0 9
Seq25 oU-oU 99.5±0.1 89.3±2.8 91.4 83.8 11.5
Seq25 rN-rN 99.3±0.2 85.7±7.5 93.6 83.9 10
Seq37 dT-dT 99.2±0.1 51.0±8.8 86.3 76.0 <3
Seq37 oU-oU 97.3±1.0 78.5±6.5 91.2 83.1 6.5
Seq37 rN-rN 96.4±0.6 85.9±3.3 95.9 86.7 13
Seq40 dT-dT 97.2±1.0 87.9±18.9 92.3 89.2 11.5
Seq40 oU-oU 96.9±1.3 91.0±8.1 98.9 97.6 >14
Seq40 rN-rN 94.5±1.5 91.9±14.1 94.8 95.3 >14
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independent, but are both critically important for thera-
peutic dosing. We attempted to estimate the duration of
therapeutic eﬀect by calculating the length of time for
which 50% knockdown was achieved, which is a param-
eter which includes both the maximum knockdown
achieved and the amount of silencing lost each day. This
last parameter demonstrates a clear diﬀerence between the
siRNAs with dT-dT overhangs and siRNAs with rN-rN
and oU-oU overhangs. For all the sequences rN-rN and
oU-oU overhangs yielded similar results, in all cases
having a longer duration than the respective siRNAs
with dT-dT overhangs. The improvement in duration
relative to the same sequence with dT-dT overhangs
varied from 11 to >100% in the length of time for
which 50% knockdown was achieved.
Comparison of in vitro and in vivo data
We compared the level of mRNA expression at the four
in vivo timepoints to the level of mRNA expression at both
timepoints tested in tissue culture cells to determine how
well the in vitro assay was capable of predicting the
duration of siRNA activity in vivo. Comparing any of
the in vivo timepoints to the mRNA expression at the
24-h timepoint of the in vitro assay produced no obvious
correlation between the two datasets (data not shown). A
comparison of the in vitro 120-h data with each of the
available sets from the in vivo experiment showed an
R
2 value of 0.65 at 1day, 0.89 at 3 days, 0.84 at 7 days
and 0.54 at 14 days. This indicates that the in vitro assay as
performed here provides a very strong correlation with
observed data from the in vivo studies. Additionally, the
percent of silencing retained per day, calculated over Days
1–7 in vivo and from 24 to 120h in vitro, was well
correlated (R
2=0.60; P<0.003).
Eﬀect of guide strand overhangs on cytokine release
An additional advantage of using chemically modiﬁed
siRNAs is the ability of those siRNAs to prevent or
reduce the release of cytokines by the treated cells (8).
We wanted to be certain that the diﬀerences we
observed in the loss of activity that were dependent on
chemistry or sequence were not the result of variable
cytokine responses.
Figure 2. Testing of siRNAs for maximum reduction of mRNA levels and the potency. siRNAs were tested in a range of concentrations on mouse
Hepa1–6 cells to compare both the maximum reduction of mRNA levels with each of the siRNAs and the potency. In each panel, the ﬁlled circles
are for siRNAs with dT-dT overhangs, ﬁlled squares are siRNAs with oU-oU overhangs, ﬁlled diamonds are siRNAs with rN-rN overhangs and
ﬁlled triangles are siRNAs with oN-oN overhangs. Panel (A) is Seq1, (B) Seq25, (C) Seq37 and (D) Seq40.
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kines (IL-1a, KC, IL-6, IFNg and TNFa)a t4 h
post-dosing with the 12 duplexes tested in vivo in LNP
forumation, to determine if the variation in the guide
strand overhangs had any eﬀect on immunostimulation
(Supplementary Figure S1). For the siRNAs examined
in this study, there was no apparent dependence of the
degree of cytokine release on the guide strand overhangs
or on the underlying sequence of the siRNAs.
DISCUSSION
A critical aspect of chemical modiﬁcations of siRNAs is to
improve their drug-like properties. To date, almost all
siRNAs used in animals have been chemically modiﬁed
in some form (3–6), but the exact impact of many of
these modiﬁcations on performance in vivo relative to un-
modiﬁed siRNAs has not been established. While most
studies have focused on maximal silencing achieved by
siRNAs in vitro (16,17), for therapeutic utility an
extended duration of action is in practice a required cor-
ollary. Currently available delivery mechanisms necessi-
tate intravenous delivery of the therapeutic material,
thereby increasing the need for maximizing the dosing
interval.
We ﬁrst investigated a set of 40 sequences directed
against the mouse Apob gene in assays in tissue culture
cells. From these experiments, we were able to demon-
strate that the guide strand overhang has no measurable
eﬀect on the maximal capacity of a given siRNA to reduce
the expression of the target. However, we also
demonstrated that over time, diﬀerences in the capablities
of the siRNAs to mediate silencing begin to manifest
themselves. Speciﬁcally, the dT-dT overhangs, which
are a common industry standard, have a consistently
negative eﬀect on the duration of action of siRNAs in
tissue culture cells. Interestingly, there are reports in the
literature that see no eﬀect of the guide strand overhang at
the tested timepoint (9) and those where a diﬀerence is
clearly evident (12,13). We suggest that both of these
results can be explained as the result of the timepoints
under which the experiments were carried out.
Essentially, the dependence of silencing on guide strand
overhangs is a direct result of the timepoints used in the
experiments.
We noted that duration of silencing has some sequence
dependence, and sequences with naturally long durations
of silencing may not show much overhang dependence of
silencing in vitro. We observed that an siRNA with natur-
ally long duration of silencing lost virtually no activity
Figure 3. Comparison of activity of siRNAs at 24 and 120h post-transfection. LNP-encapsulated siRNAs were tested in mouse Hepa1–6 cells to
compare the reduction of mRNA levels for each of the siRNAs over time. In all panels the ﬁlled circles indicate dT-dT overhangs, open circles
oU-oU overhangs and ﬁlled triangles indicate rN-rN overhangs. (A) Seq1, (B) Seq25, (C) Seq37 and (D) Seq40.
4794 Nucleic Acids Research, 2010,Vol.38, No. 14over the course of the experiment (Seq40) and while other
siRNAs lost as much as 30% of their activity per day
(Seq5, 25 and 37).
Further in vitro characterization of these sequences
included dose–response curves with the siRNAs in three
of the overhang chemistries and a second in vitro duration
assay using the LNP formulated siRNAs. We noted no
consistent diﬀerence in the IC50s that depended on the
guide strand chemistry (Figure 2).
We have also demonstrated that duration is a unique
parameter of siRNA function that is experimentally sep-
arable from both the maximum reduction of the target
mRNA and also from the potency of the siRNA. The
experiments, assay conditions and analysis methods
described here will allow for a much greater understanding
of this critical component of siRNA action in future
experiments.
The observed diﬀerences in the duration of activity of
the siRNAs in our experiments appear to come from two
sources. First, comparison of the four sequences with
constant overhangs demonstrates a sequence dependence
of duration. Second, comparison of the same sequence
with diﬀerent overhangs shows a clear diﬀerence
between dT-dT overhangs and rN-rN or oU-oU over-
hangs. What is particularly striking about this observation
is that there is no discernable diﬀerence in the maximum
potential for silencing activity of these siRNAs. The phe-
nomenon of diﬀerential duration of siRNAs in vivo
Figure 4. Liver Apob target mRNA reduction by siRNAs with diﬀerent guide strand overhangs. C57Bl/6 mice were intravenously injected with LNP
formulated siRNAs at a dose of 3mg/kg. Livers were harvested at various timepoints between 1day and 14 days post-dosing, and the mRNA level of
Apob relative to GAPDH was determined. siRNAs targeting the four Apob target sites with three diﬀerent guide strand overhangs are compared to
each other. In each panel the ﬁlled circles indicate dT-dT guide strand overhangs; open circles—oU-oU guide strand overhangs; ﬁlled triangles—
rN-rN guide strand overhangs. (A) Seq1, (B) Seq25, (C) Seq37 and (D) Seq40.
Figure 5. Comparison of the duration of activity of four Apob siRNA
sequences with dT-dT overhangs. Seq1—ﬁlled circles; Seq25—open
circles; Seq37—ﬁlled triangles; Seq40—open triangles.
Nucleic Acids Research, 2010,Vol.38, No. 14 4795therefore appears to be independent of their ability to
reduce the target mRNA.
In this study, we examined only relatively minor changes
to the chemical composition of the 2-nucleotide siRNA
30-overhangs of the guide strand. We identiﬁed diﬀerences
in duration of silencing in vivo between the nucleotide
overhang that has become the industry standard (thymi-
dine) and 2-O-methyl-uridine or ribonucleotides. One
interesting facet of the observation is that it is not neces-
sarily the 2-O-methyl modiﬁcation of the overhangs that
extends duration, as the ribonucleotide overhangs showed
similar performance. Indeed for one of the four tested se-
quences (Seq37), the siRNA with the ribonucleotide
overhang actually appears to have a measurably longer
duration than the siRNA with the 2-O-methyl-uridine
overhang. Instead, it appears that the thymidine overhangs
are consistently detrimental to obtaining maximum
duration of silencing from the siRNAs both in vitro and
in vivo and should therefore be avoided for any siRNA that
is intended to be developed for therapeutic purposes or for
extended action in any context.
These observations raise the critical question of how a
thymidine overhang might reduce duration of siRNA
activity. The presence of thymidine residues may expose
the siRNA to DNAses. It is also possible that dT-dT over-
hangs bind less stably to the 30 nucleotide binding pocket
of Argonaute (11), reducing stability of assembled RISC
complexes. Alternatively, the thymidine nucleotides
may be poor substrates for a beneﬁcial intracellular
activity. For example, the HEN1 methyltransferase of
Arabidopsis has been shown to have a preference for
methylating the 20OH of the 30 nucleotide of both
miRNAs and siRNAs and in fact to be incapable of
methylating the 30 nucleotide if that nucleotide is a
deoxyribonucleotide, requiring a free 30OH and 20OH on
the 30 nucleotide (18). In addition the mouse homologue of
HEN1 has been demonstrated to methylate the 30 termini
of Piwi-interacting RNAs (piRNAs) (19–22). If HEN1
methylation of the 20OH of the 30 ribonucleotide of an
exogenously introduced siRNA stabilizes the siRNA
intracellularly, then dT-dT siRNA may be more vulner-
able to degradation. By using a HEN1 substrate as the
30 nucleotide, or by using a 30 nucleotide that is already
methylated at the 20OH position (2-O-methyl-uridine), we
may be recapitulating the preferred state in vivo.
In summary, we demonstrate that it is possible to dif-
ferentiate both in vivo and in vitro siRNAs that appear to
have identical activities in vitro under conditions standard
in the ﬁeld. Furthermore, duration of activity appears to
be aﬀected by both the underlying sequence of the siRNAs
and the chemical nature of the guide strand overhangs.
Speciﬁcally, we have demonstrated that the de facto
manufacturing standard for guide strand overhangs (thy-
midine nucleotides) has a detrimental eﬀect on both
in vitro and in vivo duration of action of siRNAs.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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